Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.

Molecular diagnosis & therapy - 1 Jul 2021

Gatto Lidia, Franceschi Enrico, Tosoni Alicia, Di Nunno Vincenzo, Maggio Ilaria, Lodi Raffaele, Brandes Alba Ariela

Abstract excerpt

Diffuse low-grade gliomas account for approximately 20% of all primary brain tumors, they arise from glial cells and show infiltrative growth without histological features of malignancy. Mutations of the IDH1 and IDH2 genes constitute a reliable molecular signature of low-grade gliomas and are the earliest driver mutations occurring during gliomagenesis, representing a relevant biomarker with diagnostic,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Brain Neoplasms
Share to Enzyme Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epigenesis, Genetic

Share to Gene Expression Regulation, Neoplastic

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Molecular Targeted Therapy

Share to Prognosis

Source

Identifiers

PMID: 34095989
DOI: 10.1007/s40291-021-00537-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment.PMID 34095989Read ↗

Molecular biology and novel therapeutics for IDH mutant gliomas: The new era of IDH inhibitors.Semantic proximity Read ↗

Precision Oncology in Lower-Grade Gliomas: Promises and Pitfalls of Therapeutic Strategies Targeting IDH-MutationsSemantic proximity Read ↗

Therapies for IDH-Mutant Gliomas.Semantic proximity Read ↗

IDH Mutations in Glioma: Double-Edged Sword in Clinical Applications?Semantic proximity Read ↗

Bridging Cancer Biology with the Clinic: Comprehending and Exploiting IDH Gene Mutations in Gliomas.Semantic proximity Read ↗

Targeting IDH1/IDH2 mutations in gliomas.Semantic proximity Read ↗

State of the Art in Low-Grade Glioma Management: Insights From Isocitrate Dehydrogenase and Beyond.Semantic proximity Read ↗

Low-Grade Gliomas: A New Mutation, New Targeted Therapy, and Many Questions.Semantic proximity Read ↗

Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.Semantic proximity Read ↗

Novel IDH1-Targeted Glioma Therapies.Semantic proximity Read ↗

Isocitrate Dehydrogenase Mutations in Glioma: Genetics, Biochemistry, and Clinical IndicationsSemantic proximity Read ↗

IDH1 and IDH2 mutations in gliomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.